Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer

Jean-David Fumet 1, 2, 3, 4, * Nicolas Isambert 1 Alice Hervieu 1 Sylvie Zanetta 1 Jean-Florian Guion 1 Audrey Hennequin 1 Emilie Rederstorff 1, 2, 3, 4, 5, 6 Aurélie Bertaut 1, 2, 3, 4, 5, 6 François Ghiringhelli 1, 2, 3, 4, 5, 6
* Auteur correspondant
2 Plateforme de transfert en biologie cancérologique [Dijon]
CEP - Centre d'épidémiologie des populations, UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
4 Recherche épidémiologique [Centre Georges-François Leclerc]
UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
Abstract : 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate whether the addition of PD-L1 and CTLA-4 inhibition to oxaliplatin, fluorouracil and leucovorin (FOLFOX) increases treatment efficacy.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01862324
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : lundi 27 août 2018 - 11:49:55
Dernière modification le : mercredi 10 juin 2020 - 14:06:52

Lien texte intégral

Identifiants

Citation

Jean-David Fumet, Nicolas Isambert, Alice Hervieu, Sylvie Zanetta, Jean-Florian Guion, et al.. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. European Society for Medical Oncology, BMJ Journals, 2018, 3 (4), pp.e000375. ⟨10.1136/esmoopen-2018-000375⟩. ⟨hal-01862324⟩

Partager

Métriques

Consultations de la notice

88